Lipid Electrophile Adducts of ApoA1 (20) Carbone, D. L.; Doorn, J. A.; Kiebler, Z.; Sampey, B. P.; Petersen, D. R. Inhibition of Hsp72-mediated protein refolding by 4-hydroxy- 2-nonenal. Chem. Res. Toxicol. 2004, 17 (11), 1459–1467. (21) Carbone, D. L.; Doorn, J. A.; Kiebler, Z.; Petersen, D. R. Cysteine modiﬁcation by lipid peroxidation products inhibits protein disulﬁde isomerase. Chem. Res. Toxicol. 2005, 18 (8), 1324–1331. (22) Carbone, D. L.; Doorn, J. A.; Kiebler, Z.; Ickes, B. R.; Petersen, D. R. Modiﬁcation of heat shock protein 90 by 4-hydroxynonenal in a rat model of chronic alcoholic liver disease. J. Pharmacol. Exp. Ther. 2005, 315 (1), 8–15. (23) Alderton, A. L.; Faustman, C.; Liebler, D. C.; Hill, D. W. Induction of redox instability of bovine myoglobin by adduction with 4-hydroxy-2-nonenal. Biochemistry 2003, 42, 4398–4405. (24) Sampey, B. P.; Carbone, D. L.; Doorn, J. A.; Drechsel, D. A.; Petersen, D. R. 4-Hydroxy-2-nonenal adduction of extracellular signal-regulated kinase (Erk) and the inhibition of hepatocyte Erk- Est-like protein-1-activating protein-1 signal transduction. Mol. Pharmacol. 2007, 71 (3), 871–883. (25) Suman, S. P.; Faustman, C.; Stamer, S. L.; Liebler, D. C. Proteomics of lipid oxidation-induced oxidation of porcine and bovine oxy- myoglobins. Proteomics 2007, 7 (4), 628–640. (26) Szapacs, M. E.; Riggins, J. N.; Zimmerman, L. J.; Liebler, D. C. Covalent adduction of human serum albumin by 4-hydroxy-2- nonenal: kinetic analysis of competing alkylation reactions. Bio- chemistry 2006, 45 (35), 10521–10528. (27) Watson, A. D.; Subbanagounder, G.; Welsbie, D. S.; Faull, K. F.; Navab, M.; Jung, M. E.; Fogelman, A. M.; Berliner, J. A. Structural identiﬁcation of a novel pro-inﬂammatory epoxyisoprostane phos- pholipid in mildly oxidized low density lipoprotein. J. Biol. Chem. 1999, 274 (35), 24787–24798. (28) Subbanagounder, G.; Leitinger, N.; Schwenke, D. C.; Wong, J. W.; Lee, H.; Rizza, C.; Watson, A. D.; Faull, K. F.; Fogelman, A. M.; Berliner, J. A. Determinants of bioactivity of oxidized phospho- lipids. Speciﬁc oxidized fatty acyl groups at the sn-2 position. Arterioscler., Thromb., Vasc. Biol. 2000, 20 (10), 2248–2254. (29) Subbanagounder, G.; Wong, J. W.; Lee, H.; Faull, K. F.; Miller, E.; Witztum, J. L.; Berliner, J. A. Epoxyisoprostane and epoxycyclo- pentenone phospholipids regulate monocyte chemotactic pro- tein-1 and interleukin-8 synthesis. Formation of these oxidized phospholipids in response to interleukin-1beta. J. Biol. Chem. 2002, 277 (9), 7271–7281. (30) Podrez, E. A.; Poliakov, E.; Shen, Z.; Zhang, R.; Deng, Y.; Sun, M.; Finton, P. J.; Shan, L.; Febbraio, M.; Hajjar, D. P.; Silverstein, R. L.; Hoff, H. F.; Salomon, R. G.; Hazen, S. L. A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions. J. Biol. Chem. 2002, 277 (41), 38517–38523. (31) Podrez, E. A.; Poliakov, E.; Shen, Z.; Zhang, R.; Deng, Y.; Sun, M.; Finton, P. J.; Shan, L.; Gugiu, B.; Fox, P. L.; Hoff, H. F.; Salomon, R. G.; Hazen, S. L. Identiﬁcation of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36. J. Biol. Chem. 2002, 277 (41), 38503–38516. (32) Podrez, E. A.; Byzova, T. V.; Febbraio, M.; Salomon, R. G.; Ma, Y.; Valiyaveettil, M.; Poliakov, E.; Sun, M.; Finton, P. J.; Curtis, B. R.; Chen, J.; Zhang, R.; Silverstein, R. L.; Hazen, S. L. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic pheno- type. Nat. Med. 2007, 13 (9), 1086–1095. (33) Porter, N. A.; Caldwell, S. E.; Mills, K. A. Mechanisms of free radical oxidation of unsaturated lipids. Lipids 1995, 30 (4), 277–290. (34) Roberts, L. J.; Salomon, R. G.; Morrow, J. D.; Brame, C. J. New developments in the isoprostane pathway: identiﬁcation of novel highly reactive gamma-ketoaldehydes (isolevuglandins) and char- acterization of their protein adducts. FASEB J. 1999, 13 (10), 1157– 1168. (35) Lee, S. H.; Oe, T.; Blair, I. A. Vitamin C-induced decomposition of lipid hydroperoxides to endogenous genotoxins. Science 2001, 292 (5524), 2083–2086. (36) Tallman, K. A.; Kim, H. Y.; Ji, J. X.; Szapacs, M. E.; Yin, H.; McIntosh, T. J.; Liebler, D. C.; Porter, N. A. Phospholipid-protein adducts of lipid peroxidation: synthesis and study of new biotinylated phos- phatidylcholines. Chem. Res. Toxicol. 2007, 20 (2), 227–234. (37) Schumaker, V. N.; Puppione, D. L. Sequential ﬂotation ultracen- trifugation. Methods Enzymol. 1986, 128, 155–170. (38) England, P. M.; Lester, H. A.; Dougherty, D. A. Mapping disulﬁde connectivity using backbone ester hydrolysis. Biochemistry 1999, 38 (43), 14409–14415. (39) Spahr, C. S.; Davis, M. T.; McGinley, M. D.; Robinson, J. H.; Bures, E. J.; Beierle, J.; Mort, J.; Courchesne, P. L.; Chen, K.; Wahl, R. C.; Yu, W.; Luethy, R.; Patterson, S. D. Towards deﬁning the urinary proteome using liquid chromatography-tandem mass spectrom- research articles etry. I. Proﬁling an unfractionated tryptic digest. Proteomics 2001, 1 (1), 93–107. (40) Eng, J. K.; McCormack, A. L.; Yates, J. R. An Approach to Correlate Tandem Mass-Spectral Data of Peptides with Amino-Acid- Sequences in A Protein Database. J. Am. Soc. Mass Spectrom. 1994, 5 (11), 976–989. (41) Ham, A. J.; Caprioli, R. M.; Gross, M. L., Proteolytic Digestion Protocols. In The Encyclopedia of Mass Spectrometry, Volume 2 Biological Applications Part A: Peptides and Proteins. Elsevier Ltd.: Kidlington, Oxford, U.K., 2005; pp 10-17. (42) Hansen, B. T.; Davey, S. W.; Ham, A. J.; Liebler, D. C. P-Mod: an algorithm and software to map modiﬁcations to peptide sequences using tandem MS data. J. Proteome Res. 2005, 4 (2), 358–368. (43) Schneider, C.; Tallman, K. A.; Porter, N. A.; Brash, A. R. Two distinct pathways of formation of 4-hydroxynonenal. Mechanisms of nonenzymatic transformation of the 9- and 13-hydroperoxides of linoleic acid to 4-hydroxyalkenals. J. Biol. Chem. 2001, 276 (24), 20831–20838. (44) Wu, Z.; Wagner, M. A.; Zheng, L.; Parks, J. S.; Shy, J. M., III; Smith, J. D.; Gogonea, V.; Hazen, S. L. The reﬁned structure of nascent HDL reveals a key functional domain for particle maturation and dysfunction. Nat. Struct. Mol. Biol. 2007, 14 (9), 861–868. (45) Stahl, D. C.; Swiderek, K. M.; Davis, M. T.; Lee, T. D. Data- controlled automation of liquid chromatography/tandem mass spectrometry analysis of peptide mixtures. J. Am. Soc. Mass Spectrom. 1995, 7, 532–540. (46) Barter, P. J.; Rye, K. A. Relationship between the concentration and antiatherogenic activity of high-density lipoproteins. Curr. Opin. Lipidol. 2006, 17 (4), 399–403. (47) Kontush, A.; Chapman, M. J. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipi- demia, inﬂammation, and atherosclerosis. Pharmacol. Rev. 2006, 58 (3), 342–374. (48) Assmann, G.; Gotto, A. M., Jr. HDL cholesterol and protective factors in atherosclerosis. Circulation 2004, 109 (23 Suppl. 1), III8- 14. (49) Zheng, L.; Nukuna, B.; Brennan, M. L.; Sun, M.; Goormastic, M.; Settle, M.; Schmitt, D.; Fu, X.; Thomson, L.; Fox, P. L.; Ischirop- oulos, H.; Smith, J. D.; Kinter, M.; Hazen, S. L. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J. Clin. Invest. 2004, 114 (4), 529–541. (50) Nicholls, S. J.; Hazen, S. L. Myeloperoxidase and cardiovascular disease. Arterioscler., Thromb., Vasc. Biol. 2005, 25 (6), 1102–1111. (51) Nicholls, S. J.; Zheng, L.; Hazen, S. L. Formation of dysfunctional high-density lipoprotein by myeloperoxidase. Trends. Cardiovasc. Med. 2005, 15 (6), 212–219. (52) Peng, D. Q.; Wu, Z.; Brubaker, G.; Zheng, L.; Settle, M.; Gross, E.; Kinter, M.; Hazen, S. L.; Smith, J. D. Tyrosine modiﬁcation is not required for myeloperoxidase-induced loss of apolipoprotein A-I functional activities. J. Biol. Chem. 2005, 280 (40), 33775–33784. (53) Shao, B.; Bergt, C.; Fu, X.; Green, P.; Voss, J. C.; Oda, M. N.; Oram, J. F.; Heinecke, J. W. Tyrosine 192 in apolipoprotein A-I is the major site of nitration and chlorination by myeloperoxidase, but only chlorination markedly impairs ABCA1-dependent cholesterol trans- port. J. Biol. Chem. 2005, 280 (7), 5983–5993. (54) Shao, B.; Oda, M. N.; Bergt, C.; Fu, X.; Green, P. S.; Brot, N.; Oram, J. F.; Heinecke, J. W. Myeloperoxidase impairs ABCA1-dependent cholesterol efﬂux through methionine oxidation and site-speciﬁc tyrosine chlorination of apolipoprotein A-I. J. Biol. Chem. 2006, 281 (14), 9001–9004. (55) Shao, B.; Fu, X.; McDonald, T. O.; Green, P. S.; Uchida, K.; O’Brien, K. D.; Oram, J. F.; Heinecke, J. W. Acrolein impairs ATP binding cassette transporter A1-dependent cholesterol export from cells through site-speciﬁc modiﬁcation of apolipoprotein A-I. J. Biol. Chem. 2005, 280 (43), 36386–36396. (56) Shao, B.; O’Brien, K, D.; McDonald, T. O.; Fu, X.; Oram, J. F.; Uchida, K.; Heinecke, J. W. Acrolein modiﬁes apolipoprotein A-I in the human artery wall. Ann. N.Y. Acad. Sci. 2005, 1043, 396– 403. (57) Friedman, P.; Horkko, S.; Steinberg, D.; Witztum, J. L.; Dennis, E. A. Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids. Importance of Schiff base formation and aldol concentration. J. Biol. Chem. 2002, 277 (9), 7010–7020. (58) Chang, M. K.; Bergmark, C.; Laurila, A.; Horkko, S.; Han, K. H.; Friedman, P.; Dennis, E. A.; Witztum, J. L. Monoclonal antibodies against oxidized low-density lipoprotein bind to apoptotic cells and inhibit their phagocytosis by elicited macrophages: evidence that oxidation-speciﬁc epitopes mediate macrophage recognition. Proc. Natl. Acad. Sci. U.S.A. 1999, 96 (11), 6353–6358. Journal of Proteome Research Vol. 7, No. 10, 2008 4245